Renal biomarkers changes in dogs treated for proteinuric chronic kidney disease

Renin-angiotensin-aldosterone system inhibition (RAASi) reduces intraglomerular pressure and is a standard therapy for dogs with proteinuric chronic kidney disease (CKD). RAASi can acutely decrease glomerular filtration rate (GFR); however, its effects on the marker of GFR serum symmetric dimethylarginine (SDMA) concentration in dogs have not been specifically evaluated. The objective of this study was to evaluate changes, relative to pretreatment values, in serum SDMA concentrations in dogs with proteinuric CKD receiving RAASi therapy. This retrospective study used banked samples from 29 dogs with proteinuric CKD treated with enalapril (0.5 mg/kg PO q12h; n = 16) or telmisartan (1 mg/kg PO q24h; ...

To read the full article you must log in with your EGO codes.

Use your EGO login data to access Vet.Journal

Username

Password Show Password

Remember Me

Sign in with a passkey

Log in

• Forgot your password?
• Forgot your username?

Check who can access Vet.Journal